PBD Dimer Antibody Conjugates Linker Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates face challenges in achieving maximal efficacy with minimal toxicity, particularly in selectively delivering cytotoxic agents to tumor cells while avoiding normal cells, due to issues with drug mechanism, loading, and releasing properties.
Innovation Solution
Development of pyrrolobenzodiazepine (PBD) dimer antibody conjugates with specific linker groups attached to the C2 or N10 positions, enabling stable extracellular linkage and enzymatic activation within cells to release active PBD compounds, which do not retain linker stubs to maintain reactivity and avoid aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If antibody-drug conjugates are designed to deliver cytotoxic agents to tumor cells, then targeted delivery efficiency is improved, but toxicity to normal cells increases due to insufficient selectivity and stability
Solution Approach 1:
The patent applies preliminary action by designing linkers that are pre-configured to be stable in the extracellular environment but become activatable only after internalization into target cells. The linker structure is predetermined to resist cleavage by extracellular enzymes while containing specific peptide sequences (e.g., Val-Ala, Val-Cit) that will be cleaved by intracellular enzymes like cathepsin B, ensuring the cytotoxic agent remains bound during circulation and only releases at the target site.
Solution Approach 2:
The patent applies local quality by creating spatially differentiated stability properties of the linker: the N-terminal portion provides extracellular stability through hydrophobic interactions and hydrogen bonding with the antibody, while the C-terminal portion contains enzyme-sensitive peptide bonds that are stable extracellularly but labile intracellularly. This local differentiation of chemical properties enables the linker to provide both protection during circulation and controlled release at the target.
2Quantity of substance
If high drug loading is achieved in antibody conjugates, then cytotoxic efficacy is improved, but stability and solubility deteriorate
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the linker to include specific functional groups (amides, hydroxyls, carboxylic acids) that can form multiple stabilizing interactions with the antibody. The linker design incorporates a defined number of ethylene glycol units and specific amino acid sequences that tune the hydrophilicity and solubility parameters, allowing high drug loading while maintaining conjugate stability and solubility in physiological conditions.
3Duration of action of moving object
If linkers are designed for enzymatic cleavage to release active compounds, then drug releasing properties are improved, but premature activation and loss of specificity occur
Solution Approach 1:
The patent applies the intermediary principle by introducing a peptide-based linker that acts as a mediator between the antibody and the cytotoxic agent. The linker contains specific amino acid sequences (such as Val-Ala, Val-Cit, Phe-Ala) that serve as substrates for intracellular enzymes like cathepsin B. This intermediary structure ensures that the cytotoxic agent is transported intact to the target cell and only released after enzymatic cleavage within the cell, preventing premature activation and maintaining specificity.
4Productivity
If PBD compounds are conjugated to antibodies, then targeted delivery is achieved, but aggregation occurs due to retained linker stubs affecting reactivity
Solution Approach 1:
The patent applies the taking out principle by designing the linker to be completely cleaved from the PBD compound upon enzymatic activation. The cleavage sites are positioned such that the enzyme cuts both the bond between the linker and the antibody and the bond between the linker and the PBD, completely removing the linker stub. This ensures that the released PBD compound is free of any linker residues that could cause aggregation or interfere with its DNA-binding activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PBD dimer antibody conjugates achieve targeted and efficient delivery of cytotoxic agents to tumor sites with enhanced stability and specificity, reducing toxicity to normal cells and maintaining cytotoxic effects, as measured by standard analytical techniques like mass spectroscopy and HPLC.
Implementation Method 1
The linker is present in the bridge linking the monomer PBD units of the dimer and is generally cleaved by action of an enzyme on the linker group
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
Conjugates of an antibody that binds to HER2 with PBD dimers.